Moderna (MRNA) Gets a Hold from Bernstein

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday. The company’s shares closed yesterday at $47.73.

Introducing TipRanks MCP for Agents

• Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
• Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 20.4% and an 86.27% success rate on recommended stocks.

Currently, the analyst consensus on Moderna is a Hold with an average price target of $44.76, which is a -6.22% downside from current levels. In a report released on June 6, William Blair also maintained a Hold rating on the stock with a $0.00 price target.

Based on Moderna’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $389 million and a GAAP net loss of $1.34 billion. In comparison, last year the company earned a revenue of $107 million and had a GAAP net loss of $971 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRNA in relation to earlier this year. Last month, Noubar Afeyan, a Director at MRNA sold 9,263.00 shares for a total of $433,878.92.